明确供体淋巴细胞输注在高危血液系统恶性肿瘤中的作用 - Suppr

Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies.

作者信息

Schmid Christoph, Kuball Jürgen, Bug Gesine

机构信息

Department of Hematology and Oncology, Augsburg University Hospital, Augsburg, Germany.

Department of Hematology and Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.

出版信息

J Clin Oncol. 2021 Feb 10;39(5):397-418. doi: 10.1200/JCO.20.01719. Epub 2021 Jan 12.

DOI:10.1200/JCO.20.01719

PMID:33434060

Abstract

摘要

相似文献

Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies.

J Clin Oncol. 2021 Feb 10;39(5):397-418. doi: 10.1200/JCO.20.01719. Epub 2021 Jan 12.

Towards immunogene therapy of hematological malignancies.

Exp Hematol. 2006 Mar;34(3):251-63. doi: 10.1016/j.exphem.2005.10.004.

Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote Lysis of Leukemic Blasts in a CD1d-Dependent Manner.

Front Immunol. 2019 Jul 9;10:1542. doi: 10.3389/fimmu.2019.01542. eCollection 2019.

Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies.

Curr Opin Oncol. 2004 Mar;16(2):167-73. doi: 10.1097/00001622-200403000-00015.

Allogeneic cell-mediated immunotherapy at the stage of minimal residual disease following high-dose chemotherapy supported by autologous stem cell transplantation.

Acta Haematol. 2005;114(4):214-20. doi: 10.1159/000088412.

Graft Versus Leukemia: Current Status and Future Perspectives.

J Clin Oncol. 2021 Feb 10;39(5):361-372. doi: 10.1200/JCO.20.01801. Epub 2021 Jan 12.

Adoptive immunotherapy:insights from donor lymphocyte infusions.

Transfusion. 2000 Apr;40(4):393-5. doi: 10.1046/j.1537-2995.2000.40040393.x.

Minor histocompatibility antigens as targets of graft-versus-leukemia reactions.

Curr Opin Hematol. 2002 Nov;9(6):497-502. doi: 10.1097/00062752-200211000-00005.

Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.

J Hematother Stem Cell Res. 2002 Apr;11(2):265-76. doi: 10.1089/152581602753658457.

Immunotherapy of hematological malignancies with dendritic cells.

Hematol J. 2004;5 Suppl 3:S96-9. doi: 10.1038/sj.thj.6200431.

引用本文的文献

Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation.

Front Immunol. 2025 Jun 12;16:1563972. doi: 10.3389/fimmu.2025.1563972. eCollection 2025.

Current use of donor lymphocyte infusions after allogenic stem cell transplantation in Europe: a survey on behalf of the cellular therapy and immunobiology working party of the EBMT.

Bone Marrow Transplant. 2025 May;60(5):697-701. doi: 10.1038/s41409-025-02555-9. Epub 2025 Mar 23.

Utility of the 2024 best practice recommendations from the EBMT Cellular Therapy and Immunobiology Working Party for use of donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.

Bone Marrow Transplant. 2025 Feb;60(2):247-249. doi: 10.1038/s41409-024-02458-1. Epub 2024 Nov 15.

Genetically modified and unmodified cellular approaches to enhance graft versus leukemia effect, without increasing graft versus host disease: the use of allogeneic cytokine-induced killer cells.

Front Immunol. 2024 Oct 24;15:1459175. doi: 10.3389/fimmu.2024.1459175. eCollection 2024.

Beneficial effects of cellular immunotherapy in the prevention and treatment of posttransplant hematologic relapse of myelodysplastic neoplasms.

Ann Hematol. 2024 Dec;103(12):5261-5272. doi: 10.1007/s00277-024-06060-9. Epub 2024 Nov 6.

Maintenance Therapy Post-Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.

Curr Oncol. 2024 Oct 10;31(10):6050-6060. doi: 10.3390/curroncol31100451.

Cell-Based Treatment in Acute Myeloid Leukemia Relapsed after Allogeneic Stem Cell Transplantation.

Biomedicines. 2024 Aug 1;12(8):1721. doi: 10.3390/biomedicines12081721.

Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies: Clinical Implications and Limitations.

Cancers (Basel). 2024 Apr 22;16(8):1599. doi: 10.3390/cancers16081599.

Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens.

Blood. 2024 May 2;143(18):1856-1872. doi: 10.1182/blood.2023022343.

Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy.

Mol Cancer. 2023 Nov 11;22(1):180. doi: 10.1186/s12943-023-01889-6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies.

作者信息

Schmid Christoph, Kuball Jürgen, Bug Gesine

机构信息

Department of Hematology and Oncology, Augsburg University Hospital, Augsburg, Germany.

Department of Hematology and Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.

出版信息

J Clin Oncol. 2021 Feb 10;39(5):397-418. doi: 10.1200/JCO.20.01719. Epub 2021 Jan 12.

DOI:10.1200/JCO.20.01719

PMID:33434060

Abstract

摘要

相似文献

Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies.

J Clin Oncol. 2021 Feb 10;39(5):397-418. doi: 10.1200/JCO.20.01719. Epub 2021 Jan 12.

Towards immunogene therapy of hematological malignancies.

Exp Hematol. 2006 Mar;34(3):251-63. doi: 10.1016/j.exphem.2005.10.004.

Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote Lysis of Leukemic Blasts in a CD1d-Dependent Manner.

Front Immunol. 2019 Jul 9;10:1542. doi: 10.3389/fimmu.2019.01542. eCollection 2019.

Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies.

Curr Opin Oncol. 2004 Mar;16(2):167-73. doi: 10.1097/00001622-200403000-00015.

Allogeneic cell-mediated immunotherapy at the stage of minimal residual disease following high-dose chemotherapy supported by autologous stem cell transplantation.

Acta Haematol. 2005;114(4):214-20. doi: 10.1159/000088412.

Graft Versus Leukemia: Current Status and Future Perspectives.

J Clin Oncol. 2021 Feb 10;39(5):361-372. doi: 10.1200/JCO.20.01801. Epub 2021 Jan 12.

Adoptive immunotherapy:insights from donor lymphocyte infusions.

Transfusion. 2000 Apr;40(4):393-5. doi: 10.1046/j.1537-2995.2000.40040393.x.

Minor histocompatibility antigens as targets of graft-versus-leukemia reactions.

Curr Opin Hematol. 2002 Nov;9(6):497-502. doi: 10.1097/00062752-200211000-00005.

Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.

J Hematother Stem Cell Res. 2002 Apr;11(2):265-76. doi: 10.1089/152581602753658457.

Immunotherapy of hematological malignancies with dendritic cells.

Hematol J. 2004;5 Suppl 3:S96-9. doi: 10.1038/sj.thj.6200431.

引用本文的文献

Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation.

Front Immunol. 2025 Jun 12;16:1563972. doi: 10.3389/fimmu.2025.1563972. eCollection 2025.

Current use of donor lymphocyte infusions after allogenic stem cell transplantation in Europe: a survey on behalf of the cellular therapy and immunobiology working party of the EBMT.

Bone Marrow Transplant. 2025 May;60(5):697-701. doi: 10.1038/s41409-025-02555-9. Epub 2025 Mar 23.

Bone Marrow Transplant. 2025 Feb;60(2):247-249. doi: 10.1038/s41409-024-02458-1. Epub 2024 Nov 15.

Genetically modified and unmodified cellular approaches to enhance graft versus leukemia effect, without increasing graft versus host disease: the use of allogeneic cytokine-induced killer cells.

Front Immunol. 2024 Oct 24;15:1459175. doi: 10.3389/fimmu.2024.1459175. eCollection 2024.

Beneficial effects of cellular immunotherapy in the prevention and treatment of posttransplant hematologic relapse of myelodysplastic neoplasms.

Ann Hematol. 2024 Dec;103(12):5261-5272. doi: 10.1007/s00277-024-06060-9. Epub 2024 Nov 6.

Maintenance Therapy Post-Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.

Curr Oncol. 2024 Oct 10;31(10):6050-6060. doi: 10.3390/curroncol31100451.

Cell-Based Treatment in Acute Myeloid Leukemia Relapsed after Allogeneic Stem Cell Transplantation.

Biomedicines. 2024 Aug 1;12(8):1721. doi: 10.3390/biomedicines12081721.

Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies: Clinical Implications and Limitations.

Cancers (Basel). 2024 Apr 22;16(8):1599. doi: 10.3390/cancers16081599.

Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens.

Blood. 2024 May 2;143(18):1856-1872. doi: 10.1182/blood.2023022343.

Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy.

Mol Cancer. 2023 Nov 11;22(1):180. doi: 10.1186/s12943-023-01889-6.

Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies.

作者信息

机构信息

出版信息

相似文献

引用本文的文献